Apellis製藥 APLS 深 滬
等待開盤 11-05 09:30:00 美东时间
41.03
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 41.03
- 總市值 525.18万
- 52周最高 41.14
- 市盈率 靜 237.99
- 換手率 0.00%
- 52周最低 16.61
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 94.75
- 量 比 0
- 振 幅 0.00%
- 歷史最低 11.45
- 每 手 1
- 風險率 8.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多随着增长型产品组合大涨49% 百健上调2026年每股收益指引下限
在第三季度营收增长11%、且在Apellis的支持下增长型产品组合营收激增49%后，渤健上调了其2026年非GAAP每股收益指引的下限。
10-29 00:02
Biogen Raises 2026 EPS Guidance Floor as Growth Portfolio Jumps 49%
Biogen raised the lower end of its 2026 non-GAAP EPS guidance after Q3 revenue rose 11% and growth-portfolio revenue surged 49%, supported by Apellis.
10-29 00:01
Biogen Exec Expects Growth From Apellis Acquisition Even Without The Pipeline
Biogen Exec Expects Growth From Apellis Acquisition Even Without The Pipeline
10-28 20:45
渤健(BIIB.US)Q3业绩超预期，罕见病药物销售强劲
渤健（BIIB.US）10月28日盘前发布第三季度业绩：总营收28.04亿美元，同比增长11%，固定汇率情景下增长10%，高于市场预期的26.3亿至26.8亿美元
10-28 18:58
Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track
Annexon’s Q2 2026 earnings call covered ARCHER II’s new month 24 endpoint, initial FORWARD data and a planned Q4 tanruprubart BLA filing.
08-17 08:00
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Kailera Therapeutics appoints Nur Nicholson as Chief Technology Officer to oversee manufacturing and supply chain strategy as the company advances its obesity treatment pipeline. Nicholson, with nearly three decades of experience in pharmaceutical operations, will help ensure scalable and reliable supply capabilities to support the commercialization of Kailera's products, including its lead candidate ribupatide injection in global Phase 3 trials.
08-11 11:00
老药衰退新药接棒！收购驱动转型初见成效，百健(BIIB.US)上调全年营收指引
百健(BIIB.US)公布的季度营收和经调整后收益均超出了分析师的预期，这得益于新收购的肾脏及眼科疾病药物的销售增长。
07-29 20:10
渤健：尼达姆与公司高层会议核心要点
Needham分析师阿米·法迪亚在与渤健（Biogen）管理层会面后，将其目标价从255美元上调至256美元，维持“买入”评级。 核心业务相关要点： Spi...
06-29 23:32
